Benlysta Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Benlysta is a biologic medication known as belimumab, primarily used for the treatment of systemic lupus erythematosus (SLE), an autoimmune disease. It works by targeting and inhibiting the BLyS protein, which reduces the survival of B cells, helping to decrease disease activity and prevent organ damage. Benlysta is administered through intravenous infusion or subcutaneous injection.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main methods of benlysta administration are intravenous (IV) and subcutaneous (SC). IV administration involves delivering the medication directly into a vein, ensuring rapid absorption into the bloodstream. The clinical indications for Benlysta include systemic lupus erythematosus (SLE), lupus nephritis (LN), and other conditions. Benlysta is used by various end users, including hospitals, clinics, home care settings, and specialty pharmacies, ensuring broad accessibility and flexibility in treatment.

The benlysta market research report is one of a series of new reports from The Business Research Company that provides benlysta market statistics, including benlysta industry global market size, regional shares, competitors with a benlysta market share, detailed benlysta market segments, market trends and opportunities, and any further data you may need to thrive in the benlysta industry. This benlysta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The benlysta market size is expected to see rapid growth in the next few years. It will grow to $3,672.2 million in 2029 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to growing demand for precision medicine, growth in rare disease awareness, growing use of biologic monotherapies, rising investments in immunology, and rising government support. Major trends in the forecast period include advances in immunology, innovative drug delivery systems, collaboration with research institutions, strategic partnerships, and AI and machine learning in drug development.

The growing incidence of autoimmune diseases is anticipated to drive the growth of the benlysta market in the future. Autoimmune diseases are conditions where the immune system mistakenly attacks healthy cells, tissues, and organs. The rising prevalence of these diseases is attributed to factors such as better diagnostic methods, environmental triggers, lifestyle changes, genetic factors, and an aging population. Benlysta helps manage autoimmune diseases, particularly systemic lupus erythematosus (SLE), by targeting the B-lymphocyte stimulator (BLyS) protein, which is involved in the overactive immune response. This helps reduce the survival of harmful B cells, preventing them from attacking healthy tissues and controlling disease activity. For example, the National Health Council reported in March 2024 that autoimmune diseases affect around 50 million people in the United States, though the true number may be higher due to diagnostic challenges. Autoimmunity is increasing, with some studies suggesting an annual rise of 3% to 12%. Additionally, according to the National Library of Medicine, the global incidence of autoimmune diseases increases by 19.1% annually, with prevalence rising by 12.5% each year. Therefore, the increase in autoimmune disease cases is fueling the demand for benlysta.

The growth in healthcare spending is also expected to contribute to the expansion of the benlysta market. Healthcare expenditure covers all spending on medical services, including hospital care, pharmaceuticals, and healthcare administration. It is rising due to an aging population, the growing burden of chronic diseases, and advancements in medical technology. In addition, inflation and increasing healthcare demands are driving up costs. As a result, rising healthcare spending supports the benlysta market by increasing investments in treatments for chronic autoimmune diseases such as lupus, leading to higher demand for biologic therapies. For example, the Office for National Statistics reported in May 2024 that healthcare spending in the UK grew by 5.6% between 2022 and 2023, compared to a 0.9% increase in 2022. In 2023, UK healthcare expenditure reached approximately $317.63 billion (£292 billion). Thus, the growth in healthcare spending is boosting the benlysta market.

A significant trend in the benlysta market is the development of innovative products, such as autoinjectors, which improve treatment accessibility and convenience, especially for pediatric SLE patients. Autoinjectors are devices that allow patients to quickly and easily administer medication, often for chronic conditions or emergencies. In May 2024, GlaxoSmithKline announced that the FDA approved the Benlysta (belimumab) autoinjector for pediatric patients aged 5 years and older with SLE. This approval provides the first at-home treatment option for children who need belimumab, enabling subcutaneous administration and eliminating the need for regular clinical visits. The autoinjector enhances convenience and flexibility for caregivers, addressing the significant impact lupus has on children, including higher rates of organ damage.

The key company operating in the benlysta market is GlaxoSmithKline plc

North America was the largest region in the benlysta market in 2024. The regions covered in benlysta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the benlysta market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The benlysta market consists of sales of products such as immune system modulators, infusion equipment and biologic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Benlysta Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on benlysta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for benlysta ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The benlysta market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Route Of Administration: Intravenous (IV); Subcutaneous (SC)
• 2) By Clinical Indication: Systemic Lupus Erythematosus (SLE); Lupus Nephritis (LN); Other Related Conditions
• 3) By End Users: Hospitals; Clinics; Home Care Settings; Specialty Pharmacies
• Companies Mentioned: GlaxoSmithKline plc
• Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.